Online First

Review

Safety Management of Incretin-Based Obesity Therapy: Expert Consensus on the Use of Semaglutide and Tirzepatide

E. A. Troshina, M. B. Antsiferov, A. S. Ametov, I. G. Bakulin, G. R. Galstyan, T. N. Markova, T. I. Romantsova, N. V. Mazurina, O. M. Koteshkova

PDF (Rus)

119

Abstract

On December 3, 2025, a meeting of the expert working group was held in Moscow. The discussion focused on the safety and personalized use of tirzepatide (Tirzetta®) and semaglutide (Velgia® eco) in patients with overweight and obesity. Following the meeting, a consensus position was developed on the optimal use of incretin receptor agonists in real-world clinical practice.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).

ISSN 0375-9660 (Print)
ISSN 2308-1430 (Online)

Username
Password
	Remember me
Not a user? Register with this site Forgot your password?

User

Problems of Endocrinology

Review

Cookies policy